- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular basis for therapy resistance
Authors
Keywords
-
Journal
Molecular Oncology
Volume 4, Issue 3, Pages 284-300
Publisher
Wiley
Online
2010-04-26
DOI
10.1016/j.molonc.2010.04.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC).
- (2010) I Migliaccio et al. CANCER RESEARCH
- Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation.
- (2010) J. Baselga et al. CANCER RESEARCH
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer
- (2009) Marcus C. Tan et al. AMERICAN JOURNAL OF SURGERY
- Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
- (2009) M. D. Green et al. ANNALS OF ONCOLOGY
- Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
- (2009) K. L. Blackwell et al. ANNALS OF ONCOLOGY
- The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
- (2009) SR Young et al. BMC CANCER
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
- (2009) Marieke E. Straver et al. BREAST CANCER RESEARCH AND TREATMENT
- Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
- (2009) M Hauglid Flågeng et al. BRITISH JOURNAL OF CANCER
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations
- (2009) H. Carter et al. CANCER RESEARCH
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
- (2009) E. Yao et al. CLINICAL CANCER RESEARCH
- Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
- (2009) E. A. Rakha et al. CLINICAL CANCER RESEARCH
- A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
- (2009) K.-K. Wong et al. CLINICAL CANCER RESEARCH
- Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer
- (2009) K. Rhiem et al. CLINICAL ONCOLOGY
- HER-2 Signaling and Inhibition in Breast Cancer
- (2009) B. Browne et al. CURRENT CANCER DRUG TARGETS
- Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
- (2009) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers
- (2009) Annick Wong Wong Keet et al. INTERNATIONAL JOURNAL OF CANCER
- Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy inHER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013
- (2009) Lyndsay N. Harris et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer
- (2009) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
- (2009) Judith Hugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) Frédérique Penault-Llorca et al. JOURNAL OF CLINICAL ONCOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer
- (2009) Lisa A. Carey JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
- (2009) F. P. O'Malley et al. JNCI-Journal of the National Cancer Institute
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study
- (2009) Bella Kaufman et al. LANCET ONCOLOGY
- Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
- (2009) Monica M Reinholz et al. LANCET ONCOLOGY
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma
- (2009) Naoto Kuroda et al. Medical Molecular Morphology
- Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer
- (2009) Cathy B Moelans et al. MODERN PATHOLOGY
- Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
- (2009) Sohrab P. Shah et al. NATURE
- Complex landscapes of somatic rearrangement in human breast cancer genomes
- (2009) Philip J. Stephens et al. NATURE
- The cancer genome
- (2009) Michael R. Stratton et al. NATURE
- A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
- (2009) Pierre Farmer et al. NATURE MEDICINE
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition
- (2008) Frank Köster et al. BREAST CANCER RESEARCH AND TREATMENT
- Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
- (2008) T. Byrski et al. BREAST CANCER RESEARCH AND TREATMENT
- Early onset of breast cancer in a group of British black women
- (2008) R L Bowen et al. BRITISH JOURNAL OF CANCER
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer
- (2008) Nancy U. Lin et al. CANCER
- Low-Dose Estrogen Therapy to Reverse Acquired Antihormonal Resistance in the Treatment of Breast Cancer
- (2008) Ramona F. Swaby et al. Clinical Breast Cancer
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
- (2008) M. C.U. Cheang et al. CLINICAL CANCER RESEARCH
- DNA repair deficiency as a therapeutic target in cancer
- (2008) Sarah A Martin et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Targeted therapy for cancer using PARP inhibitors
- (2008) Christopher J Lord et al. CURRENT OPINION IN PHARMACOLOGY
- Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer
- (2008) Ayala Hubert et al. Familial Cancer
- The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer—Survival or Death?
- (2008) V. Craig Jordan JOURNAL OF CLINICAL ONCOLOGY
- Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial
- (2008) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features
- (2008) Lori J. Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- (2008) Priya Rastogi et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy
- (2008) Kan Yonemori et al. MEDICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- Stromal gene expression predicts clinical outcome in breast cancer
- (2008) Greg Finak et al. NATURE MEDICINE
- AKT1 E17K in human solid tumours
- (2008) F E Bleeker et al. ONCOGENE
- Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
- (2008) M Scaltriti et al. ONCOGENE
- The Molecular Pathology of Hereditary Breast Cancer
- (2008) J. Palacios et al. PATHOBIOLOGY
- An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer
- (2008) Kelly H. Salter et al. PLoS One
- CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
- (2008) Ranjan Chrisanthar et al. PLoS One
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PIK3CAcancer mutations display gender and tissue specificity patterns
- (2007) Silvia Benvenuti et al. HUMAN MUTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now